Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 4, 2006, Pages 233-277

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ATENOLOL; CASPOFUNGIN; CILOSTAZOL; CLOPIDOGREL; CONIVAPTAN; DIURETIC AGENT; ETORICOXIB; GLYCERYL TRINITRATE; HEPARIN; IMMUNOGLOBULIN; IVABRADINE; LEVOCETIRIZINE; MEPOLIZUMAB; NESIRITIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PEGAPTANIB; PLACEBO; PRASTERONE; PRASUGREL; RANIBIZUMAB; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; TADALAFIL; TECADENOSON; TG 100115; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN;

ANEMIA; ANGINA PECTORIS; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG RESEARCH; ECZEMA; EDEMA; EOSINOPHILIA; ERECTILE DYSFUNCTION; EYE ALLERGY; GRANULOMATOSIS; HEART FAILURE; HEART INFARCTION; HEMOPHILIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; HYPONATREMIA; HYPOPITUITARISM; ISCHEMIA; NEUTROPENIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RETINA MACULA DEGENERATION; RETINOPATHY; REVIEW; RHINITIS; SUBRETINAL NEOVASCULARIZATION; TACHYCARDIA; URTICARIA; VASCULITIS; WEGENER GRANULOMATOSIS;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 33745761521     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (259)

1. Waltzman, R. et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darhepoetin alfa (200 mcg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005, 10(8): 642.
2. Stein, M.L. et al. Anti-IL-5 therapy (mepolizumab) in hypereosinophilic syndromes and eosinophilic esophagitis: Cytokine secretion and decreased peripheral blood eosinophilia. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 225.
3. Walsh, T.J. et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49(11): 4536.
4. Tsoukas, C., Eyster, M.E., Shingo, S. et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 2006, 107(5): 1785.
5. Tardif, J.-C. et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005, 26(23): 2529.
6. Wiviott, S.D. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005, 111(25): 3366.
7. Colombo, A., Montorfano, M., Michev, I. et al. Focal sirolimus-eluting stent restenosis: An emerging problem. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-483.
8. Tsuchida, K. et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005, 96(3): 395.
9. Russell, M.E., Brito, F., Bilodeau, L., Stoerger, H., Chevalier, B., Niemela, K. Usage patterns and long-term clinical outcomes with the taxus stent in everyday clinical practice: The MILESTONE II global registry. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-327.
10. Russell, M.E., Cox, D.A., Lasala, J.M. New insights into drug-eluting stent practice: 1-year outcomes for ARRIVE 1, a prospective, multicenter US registry capturing consecutive patients treated with the taxus paclitaxel-eluting stent system. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-460.
11. Russell, M.E., Cox, D.A., Lasala, J.M. A contemporary review of the Mayo clinic risk score for in-hospital complications after percutaneous coronary intervention using the ARRIVE 1 safety surveillance registry for patients treated with the taxus paclitaxel-eluting coronary stent system. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-435.
12. Tansuphaswadikul, S., Tresukosol, D., Udayachalerm, W., Cahyadi, Y.H., Bae, J.-H., Nakamura, S. Durable clinical benefit following paclitaxel-eluting stent (taxus) deployment on the outcome of patients with very long coronary lesions: Multicenter registry 2-year results. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-473.
13. Stone, G.W., Koglin, J., Douglas, J. et al. The taxus 2.25 mm paclitaxel-eluting stent in a complex patient population: Results from the TAXUS V trial. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-450.
14. Weissman, N.J., Dawkins, K., Grube, E. et al. Predictors of target lesion revascularization after drug-eluting stent implantation: A angiographic and intravascular ultrasound of the TAXUS IV and VI studies. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-479.
15. Weissman, N.J., Dawkins, K., Grube, E. et al. Intimal hyperplasia thickness is independent of stent size in paclitaxel polymer coated (taxus) stents. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-480.
16. Russell, M.E., Hauptmann, K.-E., Silber, S., Grube, E. First four-year clinical follow-up from a randomized trial of a polymer-based, paclitaxel-eluting stent: TAXUS I. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-328.
17. Bhatt, D.L., Helton, T.J., Kumbhani, D.J., Bavry, A.A. The risk of stent thrombosis in paclitaxel stents compared to sirolimus stents. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-422.
18. Stone, G.W., Koglin, J., Satler, L. et al. Impact of glycemic status on outcomes after paclitaxel-eluting stem implantation: Results from the TAXUS V study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-453.
19. Stone, G.W., Russell, M.E., Low, R. et al. Twelve month clinical outcomes of the TAXUS V trial: Focus on stem thrombosis and late clinical benefits. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-465.
20. Stone, G.W., Russell, M.E., Koglin, J. et al. Impact of lesion calcification on the safety and efficacy of paclitaxel-eluting stems: A TAXUS V trial substudy. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-457.
21. Stone, G.W., Ellis, S.G., Russel, M.E. et al. Paclitaxel-eluting stents reduce neointimal hyperplasia in both diabetic and non-diabetic coronary arteries: A volumetric intravascular ultrasound TAXUS-IV study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-345.
22. Colombo, A., Chieffo, A., Airoldi, F. et al. Paclitaxel and sirolimus-eluting stents for the treatment of chronic total occlusions. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-412.
23. Stone, G.W., Koglin, J., Iyer, S.S. et al. Results from the 4.0 mm stem subgroup of the TAXUS V trial. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-329.
24. Luan, B., Wang, D., Wang, Z. et al. Efficacy of paclitaxel eluting stents implantation in unprotected left main coronary artery. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-521.
25. Stone, G.W., Koglin, J., DeGregorio, J. et al. Impact of high versus low pressure stem implantation techniques on 30-day and 9-month outcomes in the TAXUS V trial. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-330.
26. Thuesen, L., Rasmussen, K., Thayssen, P., Jensen, L.O., Maeng, M. Target lesion revascularization after implantation of sirolimus and paclitaxel eluting stents. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-478.
27. Park, Y.-B., Oh, B.-H., Kim, H.-S. et al. Using a paclitaxel-eluting stem is the independent predictor of 1-year clinical outcome after drug-eluting stem implantation: VERITAS registry experience. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-474.
28. Didier, C., Jacques, P., Meyer, E. et al. Paclitaxel-eluting stent implantation for unprotected and distal left main coronary artery stenosis. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-524.
29. Russell, M.E., Wijatyk, A., Grube, E. et al. TAXUS II 3-year clinical results: Durability of the benefit of polymer-based, paclitaxel-eluting stents in the treatment of de novo coronary artery lesions. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-323.
30. Kastrati, A. et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease. Meta-analysis of randomized trials. JAMA 2005, 294(7): 819.
31. Neumann, F.-J., Desmet, W.J.R. Two year results of the TROPICAL study: A multicenter non-randomized study of the cypher sirolimus-eluting stent in the treatment of patients with an instent restenotic native coronary artery lesion. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-324.
32. Tansuphaswadikul, S., Tresukosol, D., Udayachalerm, W., Cahyadi, Y.H., Bae, J.-H., Nakamura, S. Durable clinical benefit following sirolimus-eluting stent (cypher) deployment on the outcome of patients with chronic total occlusions: Multicenter registry 3-year results. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-408.
33. Yokoyama, M., Oscar, L., Ogasawara, D. et al. Effects of overlapping sirolimus-eluting stent on neointimal proliferation in long coronary lesions: Optical coherence tomography study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-448.
34. Park, S.-J., Park, S.-W., Kim, J.-J. et al. Intravascular ultrasonic predictors of angiographic restenosis after sirolimus-eluting stent implantation. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-476.
35. Mitsudo, K., Woong, Y.C., Keun, H.S., Mook, J.S., Kyeong, C.R., Hweung-Kon, H. Aneurysmal formations in sirolimus-eluting stenting for chronic total coronary occlusions (CTO). Am J Cardiol 2005,96(7, Suppl 1): Abst TCT-416.
36. Xu, B., Yao, M., Qin, X.-W. et al. Comparison of short and long-term outcomes between cypher and taxus stents in patients with complex lesion. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-423.
37. Leon, M.B., Fahy, M., Mehran, R. et al. Sirolimus-eluting stents in the treatment of intermediate lesions: Pooled analysis from six randomized trials and registries. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-334.
38. Sousa, J.E., Sousa, A., Sanches, A. et al. Six-month assessment of neointimal hyperplasia in diabetic patients treated with bare-metal or sirolimus-eluting stents: A three-dimensional intravascular ultrasound study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-337.
39. Lim, D.-S., Ro, Y.M., Shim, W.J. et al. Analysis of clinical and angiographic outcomes between cypher and taxus: Multi-center experience in Korea. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-420.
40. Prendergast, B.D., Suresh, V., Kumar, S. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) - A single-centre study comparing sirolimus-eluting and paclitaxel eluting stents. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-421.
41. Sousa, J.E., Sousa, A., Pinto, I. et al. Three-dimensional intravascular ultrasound evaluation of neointimal proliferation in diabetic patients: A randomized investigation of coronary lesions treated by cypher or taxus stent. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-425.
42. Weissman, N.J., Waksman, R., Suddath, W.O. et al. Frequency and severity of plaque prolapse within cypher and taxus stents: A sequential intravascular ultrasound analysis. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-332.
43. Lim, D.-S., Ro, Y.M., Shim, W.J. et al. Angiographic patterns of in-stent restenosis are different between sirolimus-eluting stents and paclitaxel-eluting stents. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-428.
44. Tansuphaswadikul, S., Tresukosol, D., Udayachalerm, W., Cahyadi, Y.H., Bae, J.-H., Nakamura, S. Comparison of efficacy and safety between sirolimus-eluting stent (cypher) and paclitaxel-eluting stent (taxus) on the outcome of patients with small coronary arteries: Multicenter registry in Asia. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-430.
45. Colombo, A., Sangiorgi, G.M., Cosgrave, J. et al. Sirolimus and paclitaxel eluting stent implantation for diffuse coronary in-stent restenosis. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-424.
46. Ellis, S.G. Formal matched analysis of cypher versus bare metal stents for de novo saphenous vein graft stenoses - The 420 patient SAGA (sirolimus-eluting stent and graft atherosclerosis) multicenter registry report. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-471.
47. Meier, B., Lindvall, B., Eltchaninoff, H. et al. Sirolimus-eluting coronary stents in small vessels: A comparison between SIRIUS and SVELTE trial. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-322.
48. Whitborn, R., Ormiston, J., Meredith, I. First-in-human safety and efficacy study of the endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system: ENDEAVOR I 24-month multicenter experience. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-464.
49. Ormiston, J., Kuck, K.-H., Laarman, G.-J., Kuntz, R., Fajadet, J., Wijns, W. ENDEAVOR II 12-month clinical results: A randomized, double-blind multicenter trial of the endeavor ABT-578-eluting stent system for treatment of native coronary arteries. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-462.
50. Fitzgerald, P.J., Wijns, W., Kuntz, R.E. et al. Intravascular ultrasound analysis of ABT-578 eluting phosphorylcholine-coated cobalt-chromium stents compared to bare metal stents in de novo coronary lesions: Results from the ENDEAVOR II trial. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-472.
51. Ellenbogen, K.A. et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005, 111(24): 3202.
52. Abou-Chebl, A. et al. Drug-eluting stents for the treatment of intracranial atherosclerosis. Initial experience and midterm angiographic follow-up. Stroke 2005, 36(12): e165.
53. Wallentin, L., Siegbahn, A., Jakubowski, J.A. et al. Prasugrel (CS-747) achieves significantly higher inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-388.
54. Jang, I.-K. et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis 2005, 20(3): 147.
55. Rizik, D.G. et al. A phase 1/2 trial of TG100-115, a phosphatidylinositol-3 kinase inhibitor, in acute ST-segment elevation myocardial infarction patients treated by percutaneous coronary intervention indicates acceptable safety and pharmacokinetics at the initial dose level. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abts 857-4.
56. Dangas, G. et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 2005, 45(8): 1186.
57. Tansuphaswadikul, S., Tresukosol, D., Udayachalerm, W., Cahyadi, Y.H., Bae, J.-H., Nakamura, S. Comparison of efficacy and safety between sirolimus-eluting stent (cypher) and paclitaxel-eluting stent (taxus) in unprotected left main coronary arteries: Multicenter registry in Asia. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-518.
58. Valgimigli, M., Malagutti, P., Aoki, J. et al. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: A combined RESEARCH and T-SEARCH long-term analysis. J Am Coll Cardiol 2006, 47(3): 507.
59. Peacock, W.F., IV, Holland, R., Gyarmathy, R. et al. Observation unit treatment of heart failure with nesiritide: Results from the proaction trial. J Emerg Med 2005, 29(3): 243.
60. Heywood, J.T. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine. Circulation 2005, 112(17, Suppl 2): Abst 2180.
61. Meyer, M., Forssmann, W.-G., Nitsche, K. et al. Ularitide improves hemodynamics and dyspnea in patients with decompensated congestive heart failure without deleterious effect on renal function. Circulation 2005, 112(17, Suppl 2): Abst 2181.
62. Ghali, J.K. et al. Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and euvolemic or hypervolemic hyponatremia. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abts 816-7.
63. Gaussem, P. et al. The specific thromboxane receptor antagonist S18886: Pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005, 3(7): 1437.
64. Kloner, R.A. et al. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005, 17(5): 450.
65. Guillevin, L., Mouthon, L., Cohen, P., Martinez, V. Intravenous immunoglobulins (IVIg) for relapses of ANCA-associated systemic vasculitides: Final analysis of a prospective, open and multicenter trial. Arthritis Rheum 2005, 52(9, Suppl): Abst 1752.
66. Oh, B.-H. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy, and placebo-like tolerability in patients with hypertension. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 1027-191.
67. Barragan, P., Roquebert, P.-O., Commeau, P. SIrolimus for below the KneE lesions: Mid-term results of SIKE study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-356.
68. Monson, J.P., Hinson, J.P., Walker, D., Maher, K., Kalingag, N., Brooke, A.M. Dehydroepiandrosterone (DHEA) replacement enhances IGF-I generation in hypopituitary patients on growth hormone replacement. Endocr Abstr 2005, 9: Abst P111.
69. Schott, C., Klimek, L., Hansen, I. Patients perceive levocetirizine as an effective and satisfying treatment for various allergic diseases: A multicentre observational study in Germany. Allergy Clin Immunol Int 2005(Suppl 1): Abst 724.
70. Cunningham, E.T., Jr., Adamis, AP, Altaweel, M. et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112(10): 1747.
71. Rosenfeld, P.J. et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005, 112(6): 1048.
72. Al-Juburi, A., Heif, M.M. Tegaserod use in opioid induced delayed gastric emptying. Am J Gastroenterol 2005, 100(9, Suppl): Abst 608.
73. Travis, S. et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005, 11(8): 713.
74. Reilly, M.C. et al. IBS-C patients have greater treatment satisfaction with initial and repeated use of tegaserod (T). Am J Gastroenterol 2005, 100(9, Suppl): Abst 926.
75. Mishkin, S., Yalovsky, M., Blank, D., Mishkin, D.S. Do all patients with small intestinal bacterial overgrowth (SIBO), based on a double peaked lactulose breath test (DPLBT), need antibiotics or is tegaserod an option? Am J Gastroenterol 2005, 100(9, Suppl): Abst 893.
76. Chang, T.-T. et al. A dose-ranging study of the efficacy and tolerability of entecavirin lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129(4): 1198.
77. Ishibashi, Y. et al. Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res 2005, 32(4): 218.
78. Sakalauskas, R., Malakauskas, K., Sitkauskiene, B. Efficacy and tolerability of desloratadine in subjects with seasonal allergic rhinitis in the general practice setting. Allergy Clin Immunol Int 2005(Suppl 1): Abst 736.
79. Luciuk, G., Keith, P. Effectiveness of desloratadine in the treatment of seasonal allergic rhinitis (SAR) in an open, 'real-world' setting: Results from the partners in allergy control and therapy (PACT) study. Allergy Clin Immunol Int 2005(Suppl 1): Abst 715.
80. Rolinski, J., Bartkowiak-Emeryk, M., Wolak-Sobiczewska, U., Emeryk, A. The influence of levocetirizine (LCZ) on dendritic cells in nasal lavage in patients suffering from seasonal allergic rhinitis. Allergy Clin Immunol Int 2005(Suppl 1): Abst 729.
81. Hellings, P., Jorissen, M. Levocetirizine is a highly effective treatment of seasonal allergic rhinitis: An open multicentre study in Belgium (Xpoll). Allergy Clin Immunol Int 2005(Suppl 1): Abst 725.
82. Eloy, P., Bertrand, B. Levocetirizine is highly effective in patients with seasonal allergic rhinitis not responding to treatment with other anti-histamines: An open multicenter study in Belgium (Xpoll). Allergy Clin Immunol Int 2005(Suppl 1): Abst 723.
83. Beeh, K.-M. et al. Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: A pooled analysis. Eur Respir J 2005, 26(Suppl 49): Abst P424.
84. Ayre, G. et al. Evaluating response to omalizumab (anti-IgE) in clinical practice. Eur Respir J 2005, 26(Suppl 49): Abst P422.
85. Klimek, L., Hansen, I. Levocetirizine is an effective treatment for nasal obstruction in allergic rhinitis: A multicentre observational study in Germany. Allergy Clin Immunol Int 2005(Suppl 1): Abst 726.
86. Demarteau, N., Bachert, C. Levocetirizine reduces asthma comorbidity in patients with persistent allergic rhinitis: An exploratory analysis of the XPERT trial. Allergy Clin Immunol Int 2005(Suppl 1): Abst 238.
87. Brummer-Korvenkontio, H., Herve, J.-P., Karppinen, A., Reunala, T. Levocetirizine in the treatment of mosquito-bite allergy. Allergy Clin Immunol Int 2005(Suppl 1): Abst 490.
88. Sekerel, B.E., Adalioglu, G., Tuncer, A., Alyamac, E., Keskin, O. Is montelukast effective in controlling nasal allergen challenge induced symptoms in children with allergic rhinitis: A double blind, placebo-controlled study. Allergy Clin Immunol Int 2005(Suppl 1): Abst 706.
89. Gorski, P., DuBuske, L.M., Gorska-Ciebiada, M., Ciebiada, M. Montelukast and levocetirizine in the treatment of perennial allergic rhinitis: A randomised, double blind, placebo controlled study. Allergy Clin Immunol Int 2005(Suppl 1): Abst 707.
90. Dreyfus, I., Ortonne, J.P., Grob, J.J. A pilot, multicentre, randomized, parallel group, double blind study comparing the effects of 2 different regimen desloratadine "daily" versus desloratadine "as needed" on the quality of life of adults with chronic idiopathic urticaria. Allergy Clin Immunol Int 2005(Suppl 1): Abst 648.
91. Lombardo, G., Marotta, G., Aglio, M., Lombardo, G.R., Bertuccio, O. Levocetirizine improves quality of life in chronic idiopathic urticaria. Allergy Clin Immunol Int 2005(Suppl 1): Abst 640.
92. Demarteau, N., Kapp, A. Cost-effectiveness of levocetirizine in chronic idiopathic urticaria: A pooled analysis of two randomized controlled trials. Allergy Clin Immunol Int 2005(Suppl 1): Abst 641.
93. Van Hammee, G., Ortonne, J.P. Levocetirizine improves health-related quality of life in chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P13.37.
94. Danniau, A., Kapp, A. Levocetirizine reduces significantly the "time to non-compliance" in CIU patients. Allergy Clin Immunol Int 2005(Suppl 1): Abst 646.
95. Bay, J.-O. et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005, 80(6): 782.
96. Martí Guadaño, E., Alias Tuduri, C., Pau Casanovas, L. et al. Fondaparinux as a suitable alternative in patients with delayed-type hypersensitivity reactions to heparins: Our experience. Allergy Clin Immunol Int 2005(Suppl 1): Abst 438.
97. Ochs, H., Berger, M. Conversion from intravenous to subcutaneous immunolgobulin therapy: Relationship between dose, serum trough IgG concentration and infection rate in patients with primary immune deficiency diseases. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 424.
98. Treon, S.P. et al. Phase II study of CC-5013 (Revlimid) and rituximab in Waldenström's macroglobulinemia: Preliminary safety and efficacy results. Blood 2005, 106(11): Abst 2443.
99. Reunala, T., Burri, P., Brummer-Korvenkontio, H., Karppinen, A. Levocetirizine is effective for delayed mosquito-bite reactions. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.64.
100. Fätkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11(11): 1170.
101. Droste, J.A.H. et al. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr 2006, 41(1): 37.
102. Gallant, I.E. et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354(3): 251.
103. Breedt, J. et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49(11): 4658.
104. Hausfeld, J.N., Brook, I. Recovery of interfering bacteria in the nasopharynx following antimicrobial therapy of acute maxillary sinusitis with telithromycin or amoxicillin-clavulanate. Antimicrob Agents Chemother 2005, 49(11): 4793.
105. Pfaller, M.A. et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 2005, 49(11): 4795.
106. Pitisuttithum, P., Negroni, R., Graybill, J.R. et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56(4): 745.
107. Lipsky, B.A. et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005, 366(9498): 1695.
108. Bril, V., Buchanan, R.A. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006, 29(1): 68.
109. Pozzilli, P. et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metab Clin Exp 2005, 54(7): 930.
110. Gumbiner, B., Mitchel, Y., Davies, M.J. et al. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. Circulation 2005, 112(17, Suppl 2): Abst 1086.
111. Kastelein, J.J., Von Bergmann, K., Sudhop, T., Trip, M.D., Jakulj, L., Vissers, M.N. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: Effects on plasma lipid levels. Circulation 2005, 112(17, Suppl 2): Abst 1080.
112. Thuren, T. et al. Effects of torcetrapib and/or atorvastatin on high-density lipoprotein and low-density lipoprotein particle size and composition: Results from a phase 2 trial. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 981-195.
113. Barrett, H., Watts, G., Pearce, G., Johnson, A., Sprecher, D.L. Effects of a peroxisome proliferator activated receptor (PPAR) delta agonist on apolipoprotein B-100 kinetics in the metabolic syndrome. Circulation 2005, 112(17, Suppl 2): Abst 1211.
114. Fagerberg, B. et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 2005, 48(9): 1716.
115. Griesing, T., Phillips, K., Otte, A., Cousins, M., Siddall, P. Treatment of chronic central neuropathic pain (NeP) after spinal cord injury (SCI) with pregabalin: Findings from a double-blind, placebo-controlled trial. J Neurol Sci 2005, 238(Suppl I): Abst OPL155.
116. Silverberg, S.J., Johnson, M., Sliney, J., Rubin, M.R. DHEA supplementation does not change bone turnover in postmenopausal osteopenic women. J Bone Miner Res 2005, 20(Suppl 1): Abst SU424.
117. Siffert, J., Sant, M., Murphy, T.K. et al. The efficacy, safety, and tolerability of pregabalin treatment for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia: Findings from the analysis of 10 randomized clinical trials. J Neurol Sci 2005, 238(Suppl 1): Abst 1580.
118. Guevara-Aguirre, J. et al. Comparison of once- and twice-daily dosing with rhIGF-1 in IGF-1 deficient subjects. Horm Res 2005, 64(Suppl 1): Abst P2-576.
119. Bloom, B. et al. Multicenter study to assess safety and efficacy of INH-A21 a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005, 24(10): 858.
120. Kuis, W., Cuppen, M., Van Furth, A.M., Kuijk, L., Frenkel, J. Anakinra in mevalonate kinase deficiency. Clin Exp Rheumatol 2005, 23(3, Suppl 37): Abst P-198.
121. Mease, P. et al. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT. J Eur Acad Dermatol Venereol 2005, 19(Suppl2): Abst P06.12.
122. Weinberg, M.A., Sasso, E.H., Perdok, R. et al. Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT. Arthritis Rheum 2005, 52(9, Suppl): Abst 500.
123. Perez, J.L., Sasso, E.H., Van Riel, P.L., Keystone, E.C., Landewe, R.B.M., Van der Heijde, D.M.F.M. Adalimumab (Humira) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis. Arthritis Rheum 2005, 52(9, Suppl): Abst 207.
124. Spencer-Green, G.T., Dietz, B.M., Sterz, R., Cifaldi, M.A., Breedveld, F.C., Weisman, M.H. Improvements in quality of life measures from adalimumab (Humira) plus methotrexate (MTX) translate into improved physical function and less fatigue in patients with early rheumatoid arthritis (RA). Arthritis Rheum 2005, 52(9, Suppl): Abst 1017.
125. Lasbleiz, S., De Bie, B., Saint-Marcoux, B., De Bandt, M. Treatment of systemic idiopathic juvenile arthritis with anakinra, one new case. Clin Exp Rheumatol 2005, 23(3, Suppl 37): Abst P-248.
126. Pascual, V., Stichweh, D., Allantaz, F., Punaro, L. Clinical and microarray follow-up of systemic onset juvenile idiopathic arthritis patients treated with anakinra. Arthritis Rheum 2005, 52(9, Suppl): Abst 616.
127. Collins, M.T., Adams, J.S., Kelly, M.H., Cutler, C., Geller, J.L. Cinacalcet is associated with decreased serum FGF-23 and improved phosphorous homeostasis in patients with tumor-induced osteomalacia. J Bone Miner Res 2005, 20(Suppl 1): Abst SA454.
128. Wernicke, J.F., Iyengar, S., D'Souza, D.N., Rosen, A., Pritchett, Y.L., Arnold, L.M. Duloxetine in the treatment of fibromyalgia in women - Results from two clinical trials. Arthritis Rheum 2005, 52(9, Suppl): Abst 652.
129. Cortelezzi, A., Maresta, A., Manara, M. et al. Improvement of markers endothetial damage in patients with pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSc) after bosentan treatment. Arthritis Rheum 2005, 52(9, Suppl): Abst 356.
130. Shoenfeld, Y., Goddard, G., Rovensky, J. et al. Treatment of 100 patients having systemic lupus erythematosus with intravenous immunoglobulin. Allergy Clin Immunol Int 2005(Suppl 1): Abst 761.
131. Greenspan, S.L. et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): Results from the TOP study. J Bone Miner Res 2005, 20(Suppl 1): Abst 1222.
132. Ting, P., Dytoc, M. Use of calcipotriol-beta methasone dipropionate ointment for morphea: A case report. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P06.54.
133. Santora, A., He, W., Lamotta, A. et al. The effect of a once-weekly tablet containing alendronate and vitamin D3 for the treatment of osteoporosis. J Bone Miner Res 2005, 20(Suppl 1): Abst M353.
134. Wagener, M.D., Cuenot, S., Lamy, O., Krieg, M. First experience with teriparatide as treatment of severe osteoporosis in daily routine in Switzerland. Bone 2005, 36(Suppl 2): Abst P684-Tu.
135. Cundy, T. et al. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005, 353(9): 918.
136. Pareja-Lazaro, M.A., Munoz-Gil, S., Ivorra-Cortes, J. et al. Long-term efficacy and safety of bosentan in the treatment of ischemic digital ulcers, Raynaud's phenomenon and cutaneous fibrosis in patients with systemic sclerosis. Arthritis Rheum 2005, 52(9, Suppl): Abst 1577.
137. Davis, J., Kupper, H., Wong, R. et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: The ATLAS trial. Arthritis Rheum 2005, 52(9, Suppl): Abst 691.
138. Van der Heijde, D., Kupper, H., Wong, R. et al. Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: The ATLAS trial. Arthritis Rheum 2005, 52(9, Suppl): Abst 483.
139. Inman, R., Wong, R., Keystone, E., Rahman, P., Maksymowych, W.P. Efficacy of adalimumab in active ankylosing spondylitis (AS) - Results of the Canadian AS study. Arthritis Rheum 2005, 52(9, Suppl): Abst 505.
140. Gossec, L., van der Heijde, D., Melian, A. et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005, 64(11): 1563.
141. Burova, K. Bowen's disease incorrectly diagnosed as psoriasis: A case report detailing a modified diagnosis and successful treatment with photodynamic therapy using methyl aminolevulinate. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.71.
142. Burtness, B. et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23(34): 8646.
143. Desai, A.A. et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 2005, 16(6): 958.
144. Ball, E.D., Soiffer, R.J., Mason, J. et al. Phase I study of a
145. Rubin, E.H., Rothermel, J., Tesfaye, F. et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005, 23(36): 9120.
146. Bellnier, D.A., Greco, W.R., Nava, H., Loewen, G.M., Oseroff, A.R., Dougherty, T.J. Mild skin photosensitivity in cancer patients following injection of photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy. Cancer Chemother Pharmacol 2006, 57(1): 40.
147. Dresemann, G. Imatinib plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts) - An update on the initial 30 pts. Eur J Cancer - Suppl 2005, 3(2): Abst 501.
148. Letvak, L., Nikolova, Z., Weinkauf, B., Hosius, C., Dresemann, G. Imatinib plus hydroxyurea in pretreated non-progressive glioblastoma (GBM) - A single center phase II study. Eur J Cancer - Suppl 2005, 3(2): Abst 502.
149. Chang, S.M. et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4): 357.
150. Burstein, H.J. et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005, 23(33): 8340.
151. Hueman, M.T., Gurney, J.M., Peoples, G.E. et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005, 23(30): 7536.
152. Alomar, A., Dalmau, J., Peramiquel, L., Marcuello, E., Muret, M.P.G., Roe, E. Cutaneous side-effects in cancer patients treated with inhibitors of the epidermal growth factor receptor: (Cetuximab, erlotinib, gefitinib). J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P04.113.
153. Cortes-Funes, H., Bovio, H., Garcia-Carbonero, R. et al. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. Eur J Cancer - Suppl 2005, 3(2): Abst 700.
154. Franklin, A., Truax, R., Mahon, M. et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. Ann Oncol 2005, 16(Suppl 2): Abst 55P.
155. Vokes, E., Haraf, D., Kayitalire, L. et al. Pemetrexed-based concurrent chemoradiotherapy (CRT) for locally advanced or metastatic non-small cell lung or esophageal cancer: A phase I dose-escalating study. Lung Cancer 2005, 49(Suppl 2): Abst PD-048.
156. de Groot, J.W.B. et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005, 78(4): 433.
157. Kato, H., Saito, M., Miura, T., Usuda, J., Okunaka, T., Furukawa, K. Advances in photodynamic therapy for central type early-stage lung cancer in Japan. Lung Cancer 2005, 49(Suppl 2): Abst P-155.
158. Thienelt, C.D. et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005, 23(34): 8786.
159. Kochupillai, V., Mohan, A., Guleria, R., Pathak, A., Bhutani, M. A pilot study of sequential therapy with gefitinib following chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 2005, 49(Suppl 2): Abst P-455.
160. Palmer, G., Graham, M., Cropp, G. et al. A phase II study of KOS-862(epothilone D) as second-line therapy in non-small cell lung cancer. Lung Cancer 2005, 49(Suppl 2): Abst P-565.
161. Wu, J., Rosado, M., Lopes, G. et al. A phase II study of oxaliplatin and docetaxel in patients with advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2005, 49(Suppl 2): Abst P-559.
162. Johnson, D., Johnson, B., Patel, J. et al. Phase II trial of erlotinib in patients with bronchioloalveolar carcinoma. Lung Cancer 2005, 49(Suppl 2): Abst O-109.
163. Soria, J., Alissa, D.O., Smit, E. et al. EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer. Lung Cancer 2005, 49(Suppl 2): Abst P-485.
164. Garfield, D.H. Modern treatment of lung cancer: Case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J Clin Oncol 2005, 23(30): 7738.
165. Baselga, J., Brennscheidt, U., Maacke, H. et al. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Lung Cancer 2005, 49(Suppl 2): Abst P-949.
166. Vergnenegre, A., Fournel, P., Perol, M., Robinet, G., Monnet, I., Chouaid, C. Gefitinib therapy of advanced non-small-cell lung cancer (NSCLC): A Markov model-based economic analysis. Lung Cancer 2005, 49(Suppl 2): Abst P-320.
167. Law, S., Au, J., Kwan, C., Leung, H., Poon, P. Retrospective review of use of gefitinib in advanced non-small cell carcinoma of lung in Chinese population. Lung Cancer 2005, 49(Suppl 2): Abst P-557.
168. Zhang, L., Zhong, W., Wang, M. et al. Efficacy and predictive marker of gefitinib in pretreated Chinese patients with advanced NSCLC. Lung Cancer 2005,49(Suppl 2): Abst P-597.
169. Vansteenkiste, J., Strobbe, E., Germonpre, P., Tits, G., Bosquee, L., Van Puijenbroek, R. Experience from a large multi-centre expanded access programme (EAP) with gefitinib ('Iressa', ZD1839) as monotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 2005, 49(Suppl 2): Abst P-587.
170. Smith, C., Mears, A., Tynan, M. et al. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (greater than or equal to 70) with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer 2005, 49(Suppl 2): Abst P-576.
171. Falcone, A., Nacci, A., Bernardini, I. et al. Clinical parameters predictive of response in advanced non-small-cell lung cancer (NSCLC) patients receiving gefitinib in an expanded access program (EAP) after failure of chemotherapy. Lung Cancer 2005, 49(Suppl 2): Abst P-583.
172. Kim, Y., Kim, S., Lee, K. et al. Clinical predictive factors, Akt phosphorylation, EGFR mutations and gefitinib activity in patients with advanced non-small-cell lung cancer. Lung Cancer 2005, 49(Suppl 2): Abst PD-146.
173. Lee, J., Moon, D., Ryu, J. et al. [18F]FLT-PET predicts response to gefitinib early after the initiation of treatment in non-smokers with adenocarcinoma of the lung. Lung Cancer 2005, 49(Suppl 2): Abst O-073.
174. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496): 1527.
175. Nagai, K., Kato, H., Tusboi, M. et al. Gefitinib in the adjuvant setting: Safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005, 16(10): 1123.
176. Li, W., Chu, D., Liu, X. et al. A Chinese, multicenter, phase II trial of gefitinib (IRESSA) in patients with non-small cell lung cancer who had failed previous chemotherapy. Lung Cancer 2005, 49(Suppl 2): Abst P-490.
177. Koschel, G., Rossi, A., Crucitta, E. et al. Phase II randomized trial of single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as front-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy. Lung Cancer 2005, 49(Suppl 2): Abst P-488.
178. Stupp, R., Leyvraz, S., Bauer, J., Zouhair, A., Luthi, F., Zimmermann, M. Gefitinib (Iressa) as first-line therapy in advanced non-small cell lung cancer. Lung Cancer 2005, 49(Suppl 2): Abst P-599.
179. Scagliotti, G., Crino, L., Herbst, R. et al. Pemetrexed (P) plus carboplatin (Cb) as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Results of both a multi-center European and an MD Anderson Cancer Center (MDACC) phase II trials. Lung Cancer 2005, 49(Suppl 2): Abst PD-083.
180. Giaccone, G. et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005, 23(28): 6854.
181. Mokhtar, N., Helal, M., Abou-Rabia, A. et al. Pemetrexed alone or in combination with cisplatin in the treatment of patients with advanced malignant mesothelioma: An open-label trial of the National Cancer Institute of Egypt. Lung Cancer 2005, 49(Suppl 2): Abst P-399.
182. Paoletti, P., Nguyen, B., Boyer, M. et al. Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer 2005, 49(Suppl 2): Abst P-435.
183. Vogelzang, N., Obasaju, C., Bloss, L. et al. A multicenter phase 2 trial of neo-adjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy (EPP) and radiation (KT) for malignant pleural mesothelioma (MPM). Lung Cancer 2005, 49(Suppl 2): Abst P-407.
184. Kindler, H., Obasaju, C., Ye, Z. et al. An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial. Lung Cancer 2005, 49(Suppl 2): Abst P-620.
185. Eisenbeis, C.F. et al. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: Evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 2005, 23(34): 8835.
186. Rosenberg, S.A., Michael, Y.J., Giao, P.Q., Attia, P. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CLTA-4. Proc Am Assoc Cancer Res 2005, 46: Abst 6180.
187. Maker, A.V., Phan, G.Q., Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23(25): 6043.
188. Comoli, P., Pedrazzoli, P., Maccario, R. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005, 23(35): 8942.
189. Rosenberg, J.E. et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma. Second-line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006, 106(1): 58.
190. Jones, L.W. et al. Rhodamine-123: Therapy for hormone refractory prostate cancer, a phase I clinical trial. J Chemother 2005, 17(4): 435.
191. Raghavan, D. et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: High subjective and objective response in patients with symptomatic metastases. J Urol 2005, 174(5): 1808.
192. Stockfleth, E., Berne, B., Talme, T. et al. A multicenter, study of MAL-PDT in immuno-compromised organ transplant recipients with non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.77.
193. Vinciullo, C., Tope, W.D., Tarstedt, M., Pariser, D., Foley, P. Patient satisfaction after treatment with MAL-PDT of basal cell carcinoma and actinic keratoses with MAL-PDT compared to previous other therapies. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.80.
194. Osuji, N.C. et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005, 90(10): 1435.
195. Alli, N., Artuz, F., Polat, M., Erbasi, S., Lenk, N., Oztas, P. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P04.39.
196. Siegert, W., Bunjes, D., Hess, G. et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: Results of a prospective phase II open-label multicenter study. J Clin Oncol 2005, 23(30): 7583.
197. Koc, O. et al. Extended follow-up and analysis with central radiological review of patients receiving FavId (Id/KLH) vaccine following rituximab. Blood 2005, 106(11): Abst 772.
198. Adim, S.B., Ozkan, A., Tunali, S., Karadogan, S.K., Baskan, E. B. A case of generalized granuloma annulare with myelodysplastic syndrome: Successful treatment with systemic isotretinoin and topical pimecrolimus 1% cream. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P09.59.
199. Pariser, D., Tarstedt, M., Braathen, M., Foley, P. An overview of the efficacy of MAL-PDT in actinic keratosis from four multicentre, randomized clinical studies. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.79.
200. Gilman, S. et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64(9): 1553.
201. Spiegel, K., Fukui, A., Lee, C., Uthman, B. Long-term add-on pregabalin treatment of patients with partial seizures: An analysis of four open-label trials. J Neurol Sci 2005, 238(Suppl 1): Abst 0176.
202. Barrett, J., Fukui, A., Huang, S., Anhut, H., Spiegel, K. Pregabalin as add-on treatment for partial seizures with or without secondary generalizations: Efficacy, safety, and tolerability findings from the analysis of four randomized clinical trials. J Neurol Sci 2005, 238(Suppl 1): Abst 0058.
203. Sobolewski, P. Assessment of the effectiveness and safety of the first adjunctive treatment of topiramate (TPM) in patients with refractory epilepsy. Epilepsia 2005, 46(Suppl 6): Abst p229.
204. Sommerville, K., Whitesides, J., Vaiciene, N., Mameniskiene, R., Rosenfeld, W., Biton, V. Safety and tolerability of intravenous lacosamide as replacement for oral lacosamide in subjects with partial-onset seizures. Epilepsia 2005, 46(Suppl 6): Abst p258.
205. Elger, C.E., Brodie, M.J., Anhut, H., Lee, C.M., Barrett, J.A. Pregabalin add-on treatment in patients with partial seizures: A novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005, 46(12): 1926.
206. Parsons, B., Albert, K.S., Almas, M., Li, C., Hamada, J., Sakai, F. Eletriptan and headache recurrence. J Neurol Sci 2005, 238(Suppl 1): Abst 1527.
207. Parsons, B., Albert, K.S., Salonen, R., Almas, M., Valade, D., Martin, V.T. Efficacy and tolerability of eletriptan in triptan-naive vs. triptan-experienced patients: Results of a combined analysis. J Neurol Sci 2005, 238(Suppl 1): Abst 1530.
208. Albert, K.S., Parsons, B., Salonen, R., Li, C., Tiseo, P., Goldstein, J. Efficacy of eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. J Neurol Sci 2005, 238(Suppl 1): Abst 1531.
209. Albert, K.S., Parsons, B., Almas, M., Lipton, R.B. Functional response in migraine: Efficacy of eletriptan using 4 concurrently administered functional assessment measures. J Neurol Sci 2005, 238(Suppl 1): Abst 1532.
210. Pitman, V., Parsons, B., Lipton, R., Linder, S., Winner, P. Efficacy and safety of oral eletriptan for the treatment of acute migraine in adolescents. J Neurol Sci 2005, 238(Suppl 1): Abst 1529.
211. Parsons, B., Albert, K.S., Almas, M. et al. Comparative efficacy of eletriptan and sumatriptan in reducing headache recurrence in high-risk migraine patients. J Neurol Sci 2005, 238(Suppl 1): Abst 1533.
212. Woitalla, D., Przuntek, H., Bremen, D., Muhlack, S., Erdmann, C., Mueller, T. Switch from levodopa/carbidopa to the corresponding stalevo dosage improves motor symptoms and elevates levodopa plasma levels in patients with Parkinson's disease. Mov Disord 2005, 20(Suppl 10): Abst P153.
213. Silva, F. Effects of CHF 1512, a new combination of levodopa methylester and carbidopa, on motor fluctuations in Parkinson's disease: Results from a European study. Mov Disord 2006, 21(Suppl 13): Abst P221.
214. Furlan, A.J., Hacke, W., Lees, K.R. Combined safety analysis of desmoteplase in acute ischemic stroke 3 to 9 hours after stroke symptom onset from two independent phase II studies (DIAS and DEDAS). J Neurol Sci 2005, 238(Suppl 1): Abst OPL065.
215. Walters, M.R. et al. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: A double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis 2005, 20(5): 304.
216. Lees, K.R. et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006, 354(6): 588.
217. Mash, D.C. Ibogaine therapy. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst S.05.05.
218. Williams, D.W., Rogers, A.K., Marquez-Caraveo, M.E. et al. Atomoxetine vs. methylphenidate in ADHD treatment: An international pediatric trial. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.7.023.
219. Allen, A.J., Feldman, P.D., Ramsey, J.L. et al. Transition from psychostimulants to atomoxetine in pediatric and adolescent patients with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.8.061.
220. Mech, A. Assessing benefits of aripiprazole in depressed and bipolar children and adolescents: A naturalistic retrospective chart review study. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.1.004.
221. Lange, S., Lotze, K., Moeller, H.J. Post-marketing surveillance of escitalopram in depressed outpatients. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.084.
222. Lenz, S.M., Pedersen, A.G. Escitalopram and suicidality in depression in adults. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.100.
223. Fantino, B., Verdoux, H., Moore, N. Escitalopram and citalopram in the treatment of outpatients with major depressive disorder. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.079.
224. Florea, I., Tonnoir, B., Arbus, C., Schmitt, L. Tolerability and efficacy of escitalopram as continuation treatment of intravenous citalopram in depressed patients. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.085.
225. Nemeroff, C., Sloan, D., Ahmed, S., Entsuah, R., Thase, M. Meta-analysis of all known randomized controlled trials comparing venlafaxine and selective serotonin reuptake inhibitors in depression. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.041.
226. Schmidt, L., Zarra, J. Venlafaxine XR versus escitalopram treatment of major depressive disorder. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.010.
227. Yamamoto, Y., McQuade, R., Carson, W. et al. Efficacy and safety of lower doses of aripiprazole in patients with acute relapse of schizophrenia. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.3.128.
228. Lane, H.-Y. et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia. A randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005, 62(11): 1196.
229. Hutchison, A.J. et al. Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron Clin Pract 2006, 102(2): c61.
230. Eardley, I. et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. BJU Int 2005, 96(9): 1323.
231. Schulman, C. et al. Long-term therapy with the dual 5α-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int 2006, 97(1): 73.
232. Basoglu, O.K. et al. Effects of aerosolized adenosine 5′-triphosphate vs adenosine 5′-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 2005, 128(4): 1905.
233. Kanniess, F. et al. Indacaterol, a novel once-daily beta2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with persistent asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 758.
234. Brookman, L. et al. Single and multiple doses of indacaterol, a novel once-daily beta2-agonist, are well tolerated in patients with mild asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 324.
235. Fogarty, C. et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization. Chest 2005, 128(4): 1980.
236. Wasserman, K., Wu, X., Garofano, R. et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 2006, 97(1): 123.
237. Balda, B.R., Ludwig, A. Acute urticaria to multiple H1 anti-histamines. Allergy Clin Immunol Int 2005(Suppl 1): Abst 468.
238. Flores-Wendt, E.R., Shopf, R. Adalimumab for psoriatic skin lesions. J Invest Dermatol 2005, 125(Suppl 1): Abst 423.
239. Hoffmann, V., Buckley, C. Calcipotriol plus beta methasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P06.57.
240. Vena, G.A., Loconsole, F., Coviello, C., Cassano, N. Treatment of psoriasis vulgaris with a beta methasone dipropionate and calcipotriol combination product is effective and safe. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P06.52.
241. Striebich, C.C. Development of inflammatory arthritis following withdraw of efalizumab (raptiva, monoclonal anti-CD11a) for psoriasis. J Invest Med 2005, 53(Suppl 1): S130.
242. Menter, A., Papp, K.A., Rosoph, L.A. et al. Results from a 36-month open-label study investigating the long-term efficacy and safety of efalizumab in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst FC13.10.
243. Van Hammee, G., Pichler, W.J. Improvement of health-related quality of life in chronic idiopathic urticaria during treatment with levocetirizine. Allergy Clin Immunol Int 2005(Suppl 1): Abst 644.
244. Quattrocchi, P., Lombardo, G.R., Lombardo, G. Desloratadine and montelukast in the treatment of acquired cold urticaria. Allergy Clin Immunol Int 2005(Suppl 1): Abst 639.
245. Martell, B.A. et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58(2): 158.
246. Zohlnhöfer, D. et al. A randomized, double-blind, placebo-controlled on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J Am Coll Cardiol 2005, 46(11): 1999.
247. Brown, N.J., Murphey, L.J., McFarlane, J.A., Scholl, F.G., Pretorius, M. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther 2005, 78(5): 477.
248. Vathsala, A. et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005, 80(6): 765.
249. Kauffman, H.M. et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80(7): 883.
250. Nathan, S., Schmidt, M., Burton, N., Ahmad, S., Barnett, S., Sherner, J.H. Voriconazole versus itraconazole for fungal prophylaxis after lung transplantation. Chest 2005, 128(4, Suppl): 342S.
251. Tyagi, S., Trehan, V., Gupta, M.D. et al. Phosphodiesterase-5 inhibitors in Eisenmenger syndrome: A new therapeutic option. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-392.
252. Zafar, M.U. et al. A phase-I study to assess the antithrombotic properties of DU-176B: An orally active direct factor-Xa inhibitor. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abts 908-161.
253. Taekema-Roelvink, M.E.J. et al. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: A double-blind, placebo-controlled study. Clin Ther 2005, 27(9): 1403.
254. Dumitrascu, D., Bocsan, C., Church, M.K., Bachvarova, A., Dimitrov, V., Popov, T. A comparison of levocetirizine and desloratadine at equiactive doses in the histamine-induced wheal and flare response in the skin in vivo. Allergy Clin Immunol Int 2005(Suppl 1): Abst 642.
255. Freestone, S., Naganuma, H., Matsushima, N. et al. A comparative study of the effects of prasugrel (CS-747, LY640315) and clopidogrel on platelet function in healthy subjects. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-374.
256. Winters, K.J., Wiviott, S.D., Farid, N.A. et al. A 60 mg loading dose of prasugrel (CS-747) is associated with more rapid onset and greater magnitude of platelet inhibition in comparison to a 300 mg loading dose of clopidogrel. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-376.
257. Iyer, G.R. et al. PRX-00023, a novel 5HT1A agonist discovered in-silico is safe and well tolerated following multiple oral dose administration in healthy subjects. Clin Pharmacol Ther 2006, 79(2): Abst PII-34.
258. Udata, C. et al. Six-day continuous IV infusion study of the safety, tolerability, and PK of ascending doses of rotigaptide (ZP123) in healthy subjects. Clin Pharmacol Ther 2006, 79(2): Abst PII-53.
259. Gibbs, M. et al. Lipid effects of torcetrapib with and without atorvastatin are optimized by morning dosing: Results from pharmacokinetic/ pharmacodynamic analyses. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 1003-186.